Boehringer Ingelheim Company Profile

What is the competitive landscape for BOEHRINGER INGELHEIM

BOEHRINGER INGELHEIM has forty-eight approved drugs.

There are sixty-nine US patents protecting BOEHRINGER INGELHEIM drugs.

There are one thousand seven hundred and seventy-four patent family members on BOEHRINGER INGELHEIM drugs in sixty-three countries and two hundred and seventeen supplementary protection certificates in nineteen countries.

Summary for Boehringer Ingelheim

International Patents:	1774
US Patents:	69
Tradenames:	37
Ingredients:	29
NDAs:	48
Patent Litigation for Boehringer Ingelheim:	See patent lawsuits for Boehringer Ingelheim
PTAB Cases with Boehringer Ingelheim as petitioner:	See PTAB cases with Boehringer Ingelheim as petitioner

Drugs and US Patents for Boehringer Ingelheim

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	GILOTRIF	afatinib dimaleate	TABLET;ORAL	201292-003	Jul 12, 2013		RX	Yes	Yes	8,426,586*PED				Y
Boehringer Ingelheim	STRIVERDI RESPIMAT	olodaterol hydrochloride	SPRAY, METERED;INHALATION	203108-001	Jul 31, 2014		RX	Yes	Yes	7,220,742		Y	Y
Boehringer Ingelheim	SYNJARDY XR	empagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208658-004	Dec 9, 2016		RX	Yes	Yes	9,949,998*PED				Y

Expired US Patents for Boehringer Ingelheim

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	MIRAPEX	pramipexole dihydrochloride	TABLET;ORAL	020667-005	Jul 1, 1997	4,843,086
Boehringer Ingelheim	OFEV	nintedanib esylate	CAPSULE;ORAL	205832-002	Oct 15, 2014	7,989,474
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-004	Jan 27, 2020	6,488,962

Paragraph IV (Patent) Challenges for BOEHRINGER INGELHEIM drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Capsules	100 mg and 150 mg		2018-10-15
	Tablets	0.25 mg		2005-05-27
	Capsules	eq. to 110 mg base		2015-12-15
	Oral Suspension	7.5 mg/5 mL		2009-12-17
	Extended-releaseTablets	2.5 mg/1000 mg 5 mg/1000 mg		2018-03-28
	Tablets	5 mg		2015-05-04
	Extended-release Tablets	2.25 mg and 3.75 mg		2011-07-26
	Extended-release Tablets	400 mg		2013-06-21
	Tablets	10 mg/5 mg and 25 mg/5 mg		2018-08-01
	Tablets	2.5 mg/500 mg, 2.5 mg/850 mg, 2.5 mg/1000 mg		2015-05-04
	Tablets	80 mg/12.5 mg and 40 mg/12.5 mg		2008-12-31
	Extended-release Capsules	25 mg and 200 mg		2007-02-01
	Tablets	0.125 mg, 0.5 mg, 1 mg and 1.5 mg		2005-06-24
	Capsules	eq. to 75 mg base and 150 mg base		2014-10-20
	Tablets	0.75 mg		2008-07-31
	Inhalation Powder Capsules	18 mcg		2018-05-11
	Tablets	5 mg/500 mg5 mg/1000 mg12.5 mg/500 mg12.5 mg/1000 mg		2018-08-01
	Extended-release Tablets	0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg		2010-06-01
	Extended-release Tablets	5 mg/1000 mg10 mg/1000 mg12.5 mg/1000 mg25 mg/1000 mg		2018-08-01
	Tablets	20 mg, 30 mg and 40 mg		2017-07-12
	Tablets	10 mg and 25 mg		2018-08-01
	Tablets	20 mg, 40 mg and 80 mg		2006-12-26
	Tablets	80 mg/25 mg		2009-02-27

International Patents for Boehringer Ingelheim Drugs

Country	Patent Number	Estimated Expiration
European Patent Office	2433665
Poland	2023902
Poland	1730131

Supplementary Protection Certificates for Boehringer Ingelheim Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0503785	CA 2011 00026	Denmark		PRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216
0966454	PA2008008,C0966454	Lithuania		PRODUCT NAME: DABIGATRANUM ETEXILATUM, MESYLATUM; REGISTRATION NO/DATE: EU/1/08/442/001-008 20080318
2187879	PA2017014,C2187879	Lithuania		PRODUCT NAME: EMPAGLIFLOZINO IR LINAGLIPTINO ARBA JO FARMACINIU POZIURIU PRIIMTINOS DRUSKOS DERINYS; REGISTRATION NO/DATE: EU/1/16/1146/001 - EU/1/16/1146/018 20161111

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Boehringer Ingelheim

Pharmaceutical Competitive Landscape Analysis: Boehringer Ingelheim – Market Position, Strengths & Strategic Insights

In the ever-evolving pharmaceutical industry, Boehringer Ingelheim stands out as a formidable player with a rich history and a strong commitment to innovation. As one of the top 20 companies in the global pharmaceutical industry, Boehringer Ingelheim has carved a niche for itself through its focus on research and development, strategic partnerships, and a diverse portfolio spanning human pharma, animal health, and biopharmaceutical contract manufacturing.

Company Overview and Market Position

Boehringer Ingelheim, founded in 1885, has maintained its status as a family-owned company for nearly 140 years. This unique ownership structure allows the company to pursue long-term strategies and invest heavily in research and development without the pressure of short-term shareholder demands.

Global Presence and Market Share

With operations in over 130 markets worldwide, Boehringer Ingelheim has established a strong global footprint. The company's net sales are primarily distributed across three main regions:

• Americas: 47.7%
• Europe: 32.3%
• Asia/Australia/Africa: 20.0%[1]

This geographical diversification helps the company mitigate risks and capitalize on growth opportunities in emerging markets.

Business Segments

Boehringer Ingelheim's operations are divided into two main business areas:

1. Human Pharma: Accounting for 81.1% of overall sales (20,774 million EUR in 2023)
2. Animal Health: Contributing 18.5% of sales (4,724 million EUR in 2023)[1]

The company also generates a small portion of revenue (0.4%) from other sales, including discontinued operations.

Strengths and Competitive Advantages

Research and Development Focus

One of Boehringer Ingelheim's key strengths lies in its unwavering commitment to research and development. In 2023, the company invested 25.1% of its net sales in R&D for Human Pharma, positioning itself among the top R&D investors in the industry[1]. This significant investment enables Boehringer Ingelheim to maintain a robust pipeline of innovative drugs and therapies.

"Innovation is at the heart of Boehringer Ingelheim. In 2023 our investments in Research & Development (R&D) in Human Pharma grew to 25.1% of net sales, which ranks us among the top R&D investors in the industry."[1]

Diverse Product Portfolio

Boehringer Ingelheim boasts a diverse product portfolio across various therapeutic areas, including:

• Cardiovascular diseases
• Respiratory diseases
• Oncology
• Immunology
• Metabolic diseases
• Central nervous system disorders
• Retinal health

This diversification helps the company spread risk and capitalize on multiple market opportunities.

Strong Market Position in Key Therapeutic Areas

The company has established a strong market position in several therapeutic areas, with flagship products like:

• JARDIANCE®: A leading treatment for type-2 diabetes that also reduces cardiovascular risks
• OFEV®: Used for treating idiopathic pulmonary fibrosis and other lung conditions

Animal Health Leadership

Boehringer Ingelheim is a market leader in Germany and the second-largest provider globally in animal health[6]. This position allows the company to leverage synergies between its human and animal health divisions, particularly in areas like immunology and infectious diseases.

Strategic Initiatives and Growth Drivers

Focus on Unmet Medical Needs

Boehringer Ingelheim's strategy revolves around addressing areas with high unmet medical needs. The company's long-term commitment allows it to invest in challenging research areas, such as mental health disorders like schizophrenia[1].

Digital Transformation and Data Analytics

Recognizing the importance of digital technologies in healthcare, Boehringer Ingelheim has been investing in digital capabilities to enhance customer experience and improve decision-making. The company has implemented a cloud-native analytics platform to process over 300 data feeds, enabling more than 60 reporting and analytics use cases across 23 business teams[4].

Strategic Partnerships and Collaborations

Boehringer Ingelheim actively seeks partnerships to bolster its pipeline and access cutting-edge technologies. Recent collaborations include:

• Partnership with 3T Biosciences, Inc. for cancer therapy research
• Collaboration with Carl Zeiss Meditec AG in eye diseases
• Partnership with IBM in artificial intelligence applications[1]

Expansion of Global Innovation Capabilities

The company continues to invest in expanding its research and development facilities globally. For instance, in 2022, Boehringer Ingelheim announced a $57 million investment to increase laboratory space and bring additional R&D capabilities to its U.S. operations[3].

Market Challenges and Opportunities

Challenges

1. Intense competition in key therapeutic areas
2. Pricing pressures and healthcare reforms in major markets
3. Regulatory hurdles and increasing costs of drug development
4. Patent expirations of key products

Opportunities

1. Growing demand for innovative treatments in areas like oncology and immunology
2. Expansion in emerging markets, particularly in the Asia/Australia/Africa region
3. Increasing focus on personalized medicine and targeted therapies
4. Potential for cross-pollination of ideas between human and animal health divisions

Financial Performance and Outlook

Boehringer Ingelheim has demonstrated strong financial performance, with net sales reaching 25,611 million EUR in 2023[1]. The company's commitment to R&D investment and focus on high-growth therapeutic areas position it well for future growth.

Key Financial Highlights (2023)

• Total net sales: 25,611 million EUR
• Human Pharma sales: 20,774 million EUR (81.1% of total)
• Animal Health sales: 4,724 million EUR (18.5% of total)
• R&D investment in Human Pharma: 25.1% of net sales[1]

Competitive Landscape Analysis

Major Competitors

Boehringer Ingelheim competes with other top pharmaceutical companies, including:

1. Pfizer
2. Novartis
3. Roche
4. Merck & Co.
5. Johnson & Johnson

Competitive Advantages

1. Strong focus on R&D and innovation
2. Diverse product portfolio across human and animal health
3. Family ownership allowing for long-term strategic planning
4. Strong market position in key therapeutic areas like diabetes and respiratory diseases

Areas for Improvement

1. Expanding presence in emerging markets
2. Accelerating digital transformation initiatives
3. Enhancing pipeline in high-growth areas like oncology and rare diseases

Future Outlook and Strategic Direction

Boehringer Ingelheim's future strategy is likely to focus on:

1. Continued investment in R&D to maintain a robust pipeline
2. Expansion of digital capabilities and data analytics
3. Strategic partnerships and collaborations to access new technologies
4. Strengthening market position in key therapeutic areas
5. Leveraging synergies between human and animal health divisions

Key Takeaways

• Boehringer Ingelheim is a top 20 global pharmaceutical company with a strong focus on innovation and R&D.
• The company's diverse portfolio spans human pharma, animal health, and biopharmaceutical contract manufacturing.
• Significant R&D investment (25.1% of net sales in Human Pharma) positions the company as a leader in innovation.
• Strong market position in key therapeutic areas like diabetes and respiratory diseases.
• Strategic focus on addressing unmet medical needs and expanding digital capabilities.
• Family ownership allows for long-term strategic planning and sustained R&D investment.
• Challenges include intense competition, pricing pressures, and the need for continued pipeline expansion.
• Future growth opportunities lie in emerging markets, personalized medicine, and cross-pollination between human and animal health divisions.

FAQs

1. Q: What percentage of Boehringer Ingelheim's sales come from Human Pharma? A: In 2023, 81.1% of Boehringer Ingelheim's sales came from the Human Pharma business segment.

2. Q: How much does Boehringer Ingelheim invest in R&D for Human Pharma? A: In 2023, Boehringer Ingelheim invested 25.1% of its net sales in R&D for Human Pharma.

3. Q: What are Boehringer Ingelheim's main business areas? A: Boehringer Ingelheim's main business areas are Human Pharma and Animal Health, with a small portion of revenue from other sales.

4. Q: What is Boehringer Ingelheim's global market position in Animal Health? A: Boehringer Ingelheim is the market leader in Germany and the second-largest provider globally in animal health.

5. Q: How is Boehringer Ingelheim leveraging digital technologies? A: Boehringer Ingelheim has implemented a cloud-native analytics platform to process over 300 data feeds, enabling more than 60 reporting and analytics use cases across 23 business teams.

Sources cited: [1] https://annualreport.boehringer-ingelheim.com/2023/download/BOE_AR23_Highlights_2023_EN_safe.pdf [3] https://gov.georgia.gov/press-releases/2022-04-20/gov-kemp-boehringer-ingelheim-expands-global-innovation-capabilities [4] https://www.zs.com/about/case-studies/boehringer-ingelheim-powers-up-with-global-cloud-platform [6] https://annualreport.boehringer-ingelheim.com/2022/downloads/2020/bi_fb_konzernlagebericht_2020_en.pdf